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CASE REPORT
Indications for and use of inferior vena cava filters in
the preoperative phase
Prabhat Bakshi POPS (proactive care of older people undergoing surgery) senior house officer,
Judith Partridge POPS clinical research fellow, Jugdeep Dhesi POPS consultant
Department of Ageing and Health, Guys and St Thomas’ NHS Foundation Trust, London SE1 7EH, UK
A 66 year old man presented for preoperative assessment and
optimisation before a left thoracoabdominal oesophagectomy
for oesophageal adenocarcinoma (T3N2). He had undergone
three cycles of chemotherapy and developed a deep vein
thrombosis in the right popliteal vein. He was started on low
molecular weight heparin. His medical history included deep
vein thrombosis of the right leg and pulmonary embolism four
years ago, myocardial infarction, hypertension, and
hypercholesterolaemia.
His history of venous thromboembolism and high ongoing
thrombotic risk meant that lifelong anticoagulation was
indicated. The need for surgery made it necessary to interrupt
therapeutic anticoagulation within two months of his venous
thromboembolism. Repeat Doppler scans of the right leg
undertaken as part of the preoperative assessment and
optimisation process showed residual thrombosis.
Questions
1 How should patients with previous venous
thromboembolism be managed preoperatively?
2 When are inferior vena cava filters indicated?
3What is the evidence for inferior vena cava filters v routine
anticoagulation in preventing primary or recurrent pulmonary
embolism?
4What complications are associated with inferior vena cava
filters?
5 When should inferior vena cava filters be removed?
Answers




Preoperative management depends on the history of venous
thromboembolism, the patient’s risk profile, the type of surgery
that is planned, and the patient’s renal function. All patients at
risk of venous thromboembolism should be prescribed
antiembolic stockings and pharmacological thromboprophylaxis
unless contraindicated.
Long answer
The importance of thromboprophylaxis in preventing deep vein
thrombosis was established more than three decades ago.1
Because deep vein thrombosis can lead to fatal pulmonary
embolism—the most common preventable risk factor for
inpatient mortality2—perioperative thromboprophylaxis has
become the norm in at risk patients. Current National Institute
for Health and Care Excellence (NICE) guidelines suggest that
any patient at risk of venous thromboembolism (for example,
previous venous thromboembolism, cancer surgery, age over
60 years, or serious comorbidity) should be prescribed
antiembolic stockings and thromboprophylaxis. Those with
normal renal function should be prescribed lowmolecular weight
heparin (0.5 mg/kg once daily), which should be omitted 12
hours before surgery. Those with an estimated glomerular
filtration rate below 30 mL/min should be given unfractionated
heparin 5000 units subcutaneously three times a day, which
again should be omitted eight hours before surgery. Insertion
of an inferior vena cava filter should be considered in those at
risk of venous thromboembolism in whom drug treatment is
contraindicated.
For patients withmore complex problems, the American College
of Chest Physicians (ACCP) provides an algorithm for risk
Correspondence to: P Bakshi pbakshi@doctors.org.uk
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;347:f5807 doi: 10.1136/bmj.f5807 (Published 30 September 2013) Page 1 of 4
Endgames
ENDGAMES
stratification and treatment based on the type of surgery planned
and the patient’s risk factors.3 According to this classification,
general surgery is associated with moderate risk, patients
undergoing surgery for cancer are higher risk, and major
orthopaedic surgery is associated with the highest possible risk.
These guidelines help identify patients who require
thromboprophylaxis after hospital discharge, such as orthopaedic
patients.
2 When are inferior vena cava filters
indicated?
Short answer
Themost common indication is in patients with acute pulmonary
embolism or deep vein thrombosis who are due to undergo
major surgery within twomonths of venous thromboembolism.
The second most common reason is venous thromboembolism
in a patient with a contraindication to anticoagulation.4
Long answer
Inferior vena cava filters are mechanical adjuncts implanted
into the inferior vena cava to prevent emboli originating in the
leg veins migrating to the pulmonary vasculature, where they
can be life threatening. Filters have been in use since 1967 and
were initially designed to be placed within the inferior vena
cava permanently.5 6 However owing to the complications and
risks involved with their implantation, their role is now limited
to cases in which anticoagulation is not possible or is inadequate
on its own. More controversial indications for the use of these
filters include prophylactic insertion in those at high risk of
deep vein thrombosis from surgery or trauma and in those with
deep vein thrombosis who have burns, cancer, or are pregnant.7-9
NICE and the ACCP recommend using these filters mainly in
the following patients:
• Patients with acute pulmonary embolism or deep vein
thrombosis who have residual deep vein thrombosis and
who have a contraindication to anticoagulation
• Those with recurrent proximal deep vein thrombosis or
pulmonary embolism despite adequate anticoagulation
• Those with acute pulmonary embolism or deep vein
thrombosis who are due to undergo major surgery within
two months of venous thromboembolism10
The British Society of Interventional Radiology collated
information on the placement of 1255 inferior vena cava filters
at 68 centres in the United Kingdom between January 2008 and
December 2010. The resulting inferior vena cava registry report
(2011) showed that the most common reason for filter insertion
was preoperatively in patients with deep vein thrombosis or
pulmonary embolism (30.3%), followed by patients with
contraindications to anticoagulation (25.6%).4 The table⇓
provides a breakdown of the indications for filter insertion.
3 What is the evidence for inferior vena cava
filters v routine anticoagulation in preventing
primary or recurrent pulmonary embolism?
Short answer
There is no evidence to support the use of vena cava filters over
drug treatment. The use of these filters in addition to routine
anticoagulation is associated with a significantly reduced
incidence of pulmonary embolism, but an increased risk of deep
vein thrombosis, and no overall survival benefit. The general
consensus remains that mechanical intervention should be used
only when no pharmacological alternative is available.
Long answer
The only randomised controlled trial in this area compared the
use of filters and anticoagulation versus anticoagulation alone
in preventing pulmonary embolism. It found a significant
reduction in pulmonary embolism (1.1% in filter group v 4.8%
without filters at 12 days postoperatively; odds ratio 0.22, 95%
confidence interval 0.05 to 0.90), but an increased risk of deep
vein thrombosis and no overall survival benefit.11 12An increased
risk of deep vein thrombosis with filter insertion had previously
been described in a population based study13
Consensus remains that filters have no overall therapeutic benefit
over anticoagulation in preventing pulmonary embolism in
uncomplicated patients. The Cardiovascular and Interventional
Radiology Society of Europe, ACCP, andNICE advise limiting
the use of filters to patients in whom no pharmacological
alternative is available.
4 What complications are associated with
inferior vena cava filters?
Short answer
Insertion is generally a safe procedure with a low major
complication risk.14 Potential complications of inferior vena
cava filters are recurrent deep vein thrombosis, migration of the
filter, and inferior vena cava thrombosis.
Long answer
A retrospective study of 400 patients with inferior vena cava
filters found deep vein thrombosis of the ipsilateral limb (the
most common complication from inferior vena cava filter
placement) in 15 (3.8%) patients and migration in six (1.5%)
patients. However, in this single centre study, inferior vena cava
thrombosis rates were high at 19 (4.75%).15 Since 2005, the US
Food andDrugAdministration has received 921 device adverse
events associated with vena cava filters. Of these, the most
common complications were filter migration (328), detachment
of device components (146), and inferior vena cava perforation
(70).16 It must be noted, however, that those cited in the FDA
report are subject to selection bias depending on the cases
reported.
Despite filter insertion being a relatively safe procedure, most
of the problems in the acute phase are associated with further
venous thromboembolism and migration of the filter. Although
the venous thromboembolism does not require further
management, migration of the filter can necessitate surgical
intervention, which in itself carries inherent risks. It is therefore
thought that inferior vena cava filters should be considered only
when routine anticoagulation is contraindicated and risk of
haemodynamically significant pulmonary embolism exists.
5 When should inferior vena cava filters be
removed?
Short answer
Inferior vena cava filters should be removed as soon as
placement is no longer needed, usually 10-14 days after insertion
and no longer than six months after. Doctors who implant such
devices are advised to ensure adequate follow-up after
implantation and to refer patients for removal when feasible.
Long answer
The general consensus among doctors is to consider filter
removal once protection from pulmonary embolism is no longer
needed. The Medicines and Healthcare Products Regulatory
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Agency (MHRA) and FDA now recommend that the doctor
who implanted the filter should be responsible for ensuring
ongoing care after implantation and for referring the patient for
filter removal once this is feasible and clinically indicated.17 18
The main reasons for removal are to mitigate filter related
complications, such as deep vein thrombosis, filter migration,
and inferior vena cava thrombosis.
Retrieval recommendations depend on the manufacturer and
the type of filter being used. Although filters may remain viable
for many years, it is generally advised that they are retrieved
10-14 days after insertion,19with the ACCP recommending that
filters be kept no longer than six months after placement.20
Despite this, retrieval rates continue to be as low as 15%,21 with
reasons including the doctor refusing to remove the filter, age,
and prolonged immobility.22
Patient outcome
An inferior vena cava filter was inserted before our patient’s
scheduled surgery. He was followed up by the surgical team
after a successful operation and the filter was subsequently
removed. He made a good recovery and has been started on
lifelong anticoagulation.
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Table
Table 1| Indications quoted by British Society of Interventional Radiology for inferior vena cava filter placement. Reproducedwith permission
from publishers of the first UK inferior vena cava filter registry report 2011 (British Society of Radiology)4
PercentageNo of patients (total 1255)Indication
11.0137Pulmonary embolism despite anticoagulation
25.6318Pulmonary embolism with contraindication to anticoagulation
4.961Deep vein thrombosis or pulmonary embolism plus limited cardiopulmonary reserve
13.3165Deep vein thrombosis with high risk of embolism
0.34Paradoxical emboli
18.4228Deep vein thrombosis with contraindication to anticoagulation
1.114Adjunct to lysis
21.0261Prophylaxis in a high risk patient
30.3376Preoperative use in acute deep vein thrombosis or pulmonary embolism
2.025Pregnant patient with deep vein thrombosis or pulmonary embolism
7.695Other
—13Unspecified
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